Previous investigations suggested that elastolytic activity found in platelets could be due to contamination by neutrophil elastase. In the present study, the lysate of blood platelets free of detectable neutrophils was examined for elastase-like activity using tertiary-butyloxycarbonyl (tBOC)-ala-ala-pro-ala-aminomethyl coumarin (I), tBOC-ala-ala-pro-val-aminomethyl coumarin (II), and succinyl-tri-ala-p-nitroanilide (SAPNA), and for elastolytic activity using 3H-labeled dog and human lung elastins. The platelet lysate degraded I at a higher rate than II, while the reverse was true of neutrophil elastase. The rate of degradation of I, II, and SAPNA by the lysate increased with reaction time up to 20 min. The rate of I, II, and SAPNA degradation by the lysate was decreased by the presence of 0.5 M NaCl, whereas NaCl greatly potentiated their degradation by neutrophil elastase. Plasma a2-macroglobulin inhibited elastolysis by the platelet lysate, whereas plasma a1-antitrypsin did not. The lysate activity was inhibited by diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, elastatinal, Trasylol, and furoyl-saccharin. The optimum pH for platelet lysate activity was 8.5-9.0, as in other studies using elastin as substrate. The pH 4.5 eluate obtained after incubation of the lysate with dog lung elastin at neutral pH exhibited the same catalytic properties as the activity in the lysate. The different substrate and inhibitor specificities and the failure of IgG specific for neutrophil elastase to remove elastaselike and elastolytic activities from the lysate indicate that a unique elastase occurs in platelets.
Introduction
Robert et al. (1) demonstrated that platelets liberate elastolytic activity. They used azo-elastin, orcein elastin, and '251/'311-labeled elastin from bovine ligamentum nuchae as substrates. The activity was found in both particulate and soluble fractions of the platelets (2, 3) . Addition of trypsin to either the initial Triton extract or to the 40% ammonium sulfate precipitate increased the capacity of the extract to degrade '25I-elastin, suggesting that a proelastase occurs in platelets. Platelet proelastase was shown to have a molecular weight of -30,000 and was converted to elastase with a molecular weight of 26,000 (4) . The elastolytic activity was enriched by affinity chromatography on elastin. Le-platelet elastase had no bound carbohydrate, and had an aminoterminal valine.
Although the foregoing evidence indicates that a unique elastase occurs in platelets, this claim was disputed by Ehrlich and Gordon (8) , who found no elastolytic activity in platelet preparations contaminated with less than one neutrophil per I18 platelets. Subsequently, Starkey et al. (9) attempted to demonstrate elastolytic activity with 3H-labeled elastin, elastin-agarose plates, and a synthetic substrate, tertiary-butyloxycarbonyl (tBOC)-L-alanine-2-naphthyl ester. No significant elastase activity was observed.
The present studies employed extracts of platelets which were free of contaminating neutrophils to determine whether there is an elastase in platelets that is different from neutrophil elastase. Substrate specificities, inhibitor profiles, and ability to bind to antibody against neutrophil elastase were utilized to establish the uniqueness of the platelet enzyme.
Methods
Materials. Bovine serum albumin (A-9647), prostaglandin El (PGE1)', Sepharose 4B, Sephadex G-200, cyanogen bromide, soybean trypsin inhibitor (SBTI), and the trypsin substrates, N-benzoyl-arginine ethyl ester HCI (BAEe) and N-a-benzoyl-D,L-arginine-p-nitroanilide (BAPNA), were obtained from Sigma Chemical-Co., St. Louis, MO. The Whatman brand of DEAE-cellulose, DE-52, was purchased from Whatman Chemical Separations, Inc., Clifton, NJ. The substrate for elastase-like activity, succinyl-tri-alanine-p-nitroanilide (SAPNA), was obtained from the Protein Research Foundation, Osaka, Japan. The fluorescence-labeled tetrapeptide substrates for elastase-like activity, tBOC-ala-ala-pro-alaaminomethyl coumarin (compound I) and tBOC-ala-ala-pro-val-aminomethyl coumarin (compound II), as well as the elastase inhibitor, furoyl-saccharin, were synthesized in one of our laboratories (Dr. Zimmerman) by previously described methods (10, 1 1) . The following inhibitors of microbial origin (12) were obtained from Peninsula Labo- ratories, Inc., Belmont, CA: elastatinal, chymostatin, antipain, and leupeptin. The purified beef lung kallikrein inhibitor, Trasylol, was a generous gift from Prof. Haberland and Dr. Spengler of Bayer AG, Elberfeld, Federal Republic of Germany.
Highly purified plasma human alpha-I-antitrypsin was prepared by the procedure of Cohen and James (13) . Human neutrophil elastase was purified to homogeneity by the procedure of Baugh and Travis (7) . Antiserum specific for human neutrophil elastase was produced in goats by this laboratory. The antiserum undiluted produced a precipitin line against the antigen at 1.0 mg/ml which was equidistant between the two wells. Purified porcine pancreatic elastase was obtained by the method of Shotton (14) , and crystalline bovine trypsin (code 36-555) was purchased from Miles Laboratories, Inc., Elkhart, IN. The trypsin was 51.4% active, as judged by active site titration usingp-nitrophenyl p-guanidino-benzoate-HCI (15) . Apyrase used in the isolation of washed platelets was purified (16) and the quantity used was sufficient to block platelet aggregation by adenosine-5'-diphosphate, ADP (20 MM), using a platelet aggregometer. Dog lung elastin, labeled with tritium using tritium gas at low pressure (17) Preparation of ar2macroglobulin free of a,-antitrypsin. These steps took advantage of the different precipitabilities of the two protease inhibitors, as well as their molecular size (13, (21) (22) (23) . The 50% ammonium sulfate precipitate from 2 ml of fresh-frozen, heparinized normal human plasma was passed through a Sephadex G-200 column (2.5 X 48 cm) in 0.05 M Tris HCI-0. I M NaCI (pH 7.5). The peak emerging at the void volume was pooled and concentrated to a volume of -4 ml using an Amicon PM-10 membrane (Amicon Corp., Danvers, MA). The con. centrate was used as a source of native a2-macroglobulin.
a1-Antitrypsin has a K., of -0.5 on Sephadex G-200, allowing for removal of any trace amounts of this inhibitor from a2-macroglobulin. The native a2-macroglobulin preparation did not inhibit the trypsin hydrolysis of small substrates (24) , e.g., BAPNA, confirming the removal of a1-antitrypsin. The preparation exhibited an immunoprecipitation band against antiserum to a2-macroglobulin but not against antiserum to a1-antitrypsin.
Assay and inactivation ofarmacroglobulin activity. The concentration of active a2-macroglobulin was determined as described by Schidlow and Kueppers (24) . In this assay, an excess of active-site titrated trypsin is added to consume all trypsin inhibitors in the test sample, including a2-macroglobulin. When SBTI is then added to inhibit excess, free trypsin, the observable activity in the presence of BAPNA is due to trypsin bound to a2-macroglobulin. This is because trypsin which is bound to a2-macroglobulin is not subject to inhibition by SBTI and is fully active against low molecular weight substrates (24) . The concentration of the a2-macroglobulin preparation used in these experiments was 0.132 mg/ml.
The nucleophilic amine, methylamine, specifically inactivates the ability of a2-macroglobulin to inhibit proteinases (25) . In order to verify the supposition that the inhibiting activity was due only to a2-macroglobulin, a sample (I ml) of the concentrate was treated as follows: the pH was adjusted to 8.0, 26 Ml of 1 M methylamine HCl was added, and the solution was incubated at 4°C overnight. For comparative purposes, a sample ofa2-macroglobulin was carried through the same steps, omitting methylamine HCI.
Immunosorbent column with IgG specificfor human neutrophil elastase. The IgG fraction from goat antiserum to human neutrophil elastase was isolated by ammonium sulfate precipitation and chromatography on DEAE-cellulose by previously described methods (26). The purified IgG was then bound to cyanogen bromide-activated Sepharose 4B (27, 28) , and the resulting immune immunosorbent material was equilibrated with 0.025 M sodium phosphate-0.5 M NaCI-0.05% Triton X-100 (pH 6.0). (29) , with minor modifications designed to remove leukocytes more effectively. Blood from volunteer donors (one donor unit -500 ml) was anticoagulated with acid citratedextrose in 50-ml aliquots and centrifuged at 225 g using swinging buckets in a Sorvall RC-3 centrifuge (DuPont-Sorvall, Newtown, CT) at room temperature for 20 min. The upper two-thirds ofthe resulting supernatant, platelet-rich plasma (PRP), was very carefully withdrawn using a plastic syringe with attached Tygon tubing and was centrifuged again in the same manner.
After the second centrifugation, the upper three-fourths ofthe contents of the tubes was carefully withdrawn and the platelets were recovered by centrifugation at 990 g at room temperature for 20 min. The pelleted platelets were then resuspended in four 40-mi volumes of Tyrode's buffer with albumin (3.5 mg/ml), dextrose (0.1 g/I00 ml), heparin (60 U/ml), PGEI (1 LM) , and apyrase (150 Mi/40 ml). After incubation for 20 min at 370C the suspensions were centrifuged in the same manner as in obtaining the platelet pellet. These steps were repeated twice without adding heparin. The platelets were then taken up in a total volume of I ml using the wash solution without heparin. This suspension was used to prepare a platelet lysate.
Platelet and total/differential leukocyte counting. Platelet Chymotrypsin-pretreated 3H-dog and human lung elastins. The 3H-dog lung elastin (5 mg) was mixed with 250 mg of unlabeled dog lung elastin and washed four times by suspension in distilled water and centrifugation, followed by washing in a similar manner with 200-ml volumes of the assay buffer containing 0.05 M Tris HCI-0. 14 M NaCl-0.2% Triton X-100 (pH 8.0). Washing was continued until <20 cpm/ml of wash supernatant was measured after centrifugation. The washed elastin was suspended in the same buffer at I mg/ml and was then pretreated (20) with a-chymotrypsin (Worthington Biochemical Corp., Freehold, NJ), code CDI 2 LX. The final product had a specific radioactivity of 1.8 X 10 cpm/mg elastin. Under the assay conditions described below, neither trypsin nor chymotrypsin were capable of releasing radioactivity from the chymotrypsin-pretreated 3H-elastin.
Human Platelet Elastase
The 3H-human lung elastin was suspended at a concentration of I mg/ml and treated in the same manner as dog elastin, except that the initial washing steps were omitted. The human elastin had a specific radioactivity of 5.7 X 10i cpm/mg elastin. Neither trypsin nor chymotrypsin was capable of releasing radioactivity from the preparation above the level observed for incubation with buffer alone.
Measurement ofelastolytic activity using chymotrypsin-pretreated 3H-dog and human lung elastins. For assays using 3H-dog lung elastin, 3-ml volumes of the material at a concentration of I mg elastin/ml in 0.05 M Tris HCl-0.14 M NaCl-0.2% Triton X-100 (pH 8.0) were added to siliconized Reacti-Vials (Pierce Chemical Co., Rockford, IL) with Teflon stirrers. The total volume of test sample and/or buffer or test reagents added to the elastin was 0.3 ml. Preliminary tests revealed that incubation at 370C resulted in rapid loss of activity of the platelet lysate.
The reaction mixtures were incubated at room temperature (230C) with constant stirring, and 0.3-ml aliquots were removed at selected times for assay of radioactivity in the supernatant following centrifugation in a Beckman Microfuge. A blank containing appropriate amounts of the buffer components of the platelet lysate and the assay buffer was included to subtract observed spontaneous release of radioactivity from the3H-elastin during the course of the assay. a,-Antitrypsin and elastatinal were diluted in assay buffer before their inhibitory capacities were tested. a,-Antitrypsin (0.5 mg) was added to the platelet lysate in a total volume of 0.3 ml and the mixture was preincubated for 10 min. Elastatinal (3 mg) was similarly preincubated with the lysate and the mixture was assayed. All values presented in the text were derived by subtracting the blank values from those of the test samples. Aliquots were diluted in BioFluor scintillation liquid (New England Nuclear, Boston, MA) and assayed in a Searle Isocap 300 liquid scintillation counter (Nuclear-Chicago Corp., Des Plaines, IL) until constant counts were observed.
Assays employing chymotrypsin-pretreated3H-human lung elastin were carried out in the same way as dog lung elastin assays. Combinations of sample volumes and the suspended radioactively labeled elastin were used as elaborated in Results.
Affinity separation on dog lung elastin. It was considered desirable for the sake of experimental continuity to use the same material for affinity separation as used in the assay of platelet lysate activity. Therefore, a sample (10 mg) of the chymotrypsin-pretreated 3H-dog lung elastin was used in an experiment to separate elastolytic activity from the platelet lysate using the methodology of Legrand et al. (4) .
Determination ofthe pH dependence ofplatelet elastase-like activity.
The effect of pH on the hydrolysis of compound I was determined using the material derived by affinity separation of activity from the rest of the platelet lysate on the elastin. The buffer employed was 0.04 M Tris HCI (pH 7.5). Different pH values were obtained by the addition of concentrated HCO or NaOH. Determination of the apparent mass ratio ofplatelet lysate enzyme.
The platelet lysate prepared from washed platelets was dialyzed against 0.05 M sodium acetate (pH 4.5) for a period of 2 h at 4°C with three changes. The dialyzed sample was centrifuged, and the clear supernatant material was injected onto an I-250 protein column for gel filtration by high-pressure liquid chromatography (Waters Associates, Inc., Milford, MA). The flow rate was maintained at 1 ml/min, and 0.5-ml fractions were collected. The activity in the fractions for hydrolysis of compound I was measured immediately upon elution, using an equal volume (0.5 ml) of the substrate at a concentration of 0.4 mM. Molecular weight standards (Blue Dextran 2000, albumin, chymotrypsinogen A, and ribonuclease A) were obtained from Pharmacia Fine Chemicals, Piscataway, NJ. The elution time for the platelet enzyme was determined by activity measurements on collected fractions. A plot of log of the apparent mass ratio of standards versus elution time was then used to estimate the apparent mass ratio for the platelet enzyme.
Results
Removal ofleukocytes during platelet purification. A total of 8.3
X 10'°p latelets, or 64% ofthe average number of platelets present (-1.3 X 10" ) in a donor unit of blood (33) , was present in the The platelet elastase-like activity was also compared with that of neutrophil elastase with the commonly used substrate, SAPNA. Although the rate of hydrolysis of SAPNA in the lysate was quite low (change in absorbance at 410 nm of 0.00036 U/ min for 20 ,l of the lysate), it was found to increase with time, approximately doubling after 20 min of incubation. When NaCl was added to the reaction mixture at 20 min, the activity of the platelet lysate was inhibited. In contrast, neutrophil elastase hydrolyzed SAPNA at a constant rate (change in absorbance at 410 nm of 0.0024 U/min for I Mg of the enzyme), and the activity was increased about twofold by NaCl.
Effects ofinhibitors on the elastase-like activity ofthe platelet lysate and neutrophil elastase. A number of organic and inorganic reagents were tested to determine whether they inhibit the elastase-like activity of the platelet lysate and neutrophil elastase. Compound I was used to evaluate inhibition of platelet lysate (20 Ml), and SAPNA was used for neutrophil elastase (I M4g). The irreversible serine protease inhibitors, DFP (20 mM) and PMSF (25 mM), produced 33.5% and 75.0% inhibition, respectively, of the lysate activity. They produced 100% inhibition of neutrophil elastase activity. Furoyl-saccharin (0.25 mg/ml) inhibited lysate activity by 50.9% and neutrophil elastase by 100%. Mercaptoethanol (I mM) and EDTA (25 mM), not known to alter the activity of neutrophil elastase, likewise had no effect on platelet lysate activity. Addition of HgCl2 to the reaction mixture with the platelet lysate resulted in extreme turbidity and apparent complete inhibition. However, when the precipitated material was reconstituted in a new reaction mixture without HgCl2, -50% of the activity was regained. This indicates a nonspecific removal of the platelet lysate activity by metal ion precipitation, rather than involvement of a sulfhydryl moiety.
Purified a,-antitrypsin had no effect on the elastase-like activity of the platelet lysate (Table I ). This unexpected finding illustrates the most outstanding difference between the platelet lysate and neutrophil elastase activities. Trasylol inhibited both the activity in the lysate and neutrophil elastase. Elastatinal was also an effective inhibitor of both the lysate activity and of neutrophil elastase. The remaining three bacterial inhibitors, chymostatin, antipain, and leupeptin, had no effect on the lysate activity or on neutrophil elastase.
Inhibition of neutrophil elastase and other proteases by the platelet lysate. Platelets are known to contain a,-antitrypsin and a2-macroglobulin (34, 35) and perhaps other protease inhibitors. In assay systems for protease inhibitors which use low molecular weight substrates (36), inhibition of enzymes by a2-macroglob- (Table II) . The lysate inhibits much more neutrophil elastase activity than pancreatic elastase or trypsin activity. Degradation of3H-dog lung elastin by the platelet lysate. An enzyme referred to as an elastase should be capable ofdegrading native elastin. The capacity ofthe platelet lysate to degrade chymotrypsin-pretreated 3H-dog lung elastin was tested (Fig. 3) . Elastolytic activity using this substrate was found to be linear over a 3-h period and for release of up to 4,000 cpm/ 150 gl of supernatant tested in the assay. As evinced by Fig. 3 , a,-antitrypsin did not inhibit platelet lysate elastolytic activity. However, the highly specific elastase inhibitor, elastatinal, was an effective inhibitor of elastolysis by the platelet lysate. The elastolytic activity ofthe platelet lysate (100 ,g) was equivalent to that of0.63 ,ug of neutrophil elastase or 0.42 Ag of porcine pancreatic elastase.
Inhibition of the elastolytic activity ofthe platelet lysate by armacroglobulin. The ability of a2-macroglobulin to inhibit elastolysis by platelet lysate and neutrophil elastase was measured using 3H-labeled human lung elastin. Appropriate amounts of (Figs. 4 A and B) . The neutrophil elastase and platelet lysate activities were inhibited by 66.0% and 68.4%, respectively. Methylamine-inactivated a2-macroglobulin did not inhibit neutrophil elastase or the platelet lysate elastolytic activities. Immunologic differentiation ofplatelet lysate elastase-like and elastolytic activities from neutrophil elastase. An immunosorbent column with purified goat IgG from immune serum against human neutrophil elastase and a control column with purified goat IgG from nonimmune serum were employed to further test whether the elastase-like and elastolytic activities of the platelet lysate could be related to neutrophil elastase. Amounts of neutrophil elastase and platelet lysate that had the same capacity to degrade compound I were utilized. Recovery of elastase-like activity from these columns is shown for neutrophil elastase in Fig. 5 A and for platelet lysate in Fig. 5 B. The column buffer was chosen to minimize the adsorptive effect (observed in preliminary experiments) of the column supporting material toward neutrophil elastase without interfering with the antigen-antibody interaction. Data shown in Fig. 5 A reveal that neutrophil elastase could be specifically removed by the immune IgG column. -93% of the activity applied was recovered from the nonimmune IgG column and 17% from the immune IgG column. Data in Fig. 5 B show that platelet elastase-like activity did not bind to either column. Calculated recoveries of activity were 102.8% from the nonimmune and 104.3% from the immune IgG column.
Preliminary attempts to test aliquots of the platelet lysate fractions from these columns (as in Fig. 5 B) for elastolytic activity using 3H-human lung elastin were unsuccessful because low levels of activity had been added to the column. To resolve this problem, an identical set of columns (Fig. 5 B) were run, and fractions 7-12 (corresponding to the bulk of the eluted elastase-like activity) were recovered and concentrated by Amicon PM-10 membrane to a volume of 2.5 ml. To this concentrated fraction, 2 ml of 3H-human lung elastin (1.5 mg/ml water) was added. The pH was then adjusted to 8.0 and the samples were incubated at room temperature. Controls included a sample of platelet lysate equivalent to that applied to the column and a blank prepared with appropriate buffer components. Both were mixed with 3H-elastin and carried through the same steps. At 4 and 20 h, 700-,ul aliquots of the mixtures were centrifuged in a Beckman Microfuge and radioactivity was measured in 500-MI aliquots ofthe supernatants tested for 3H associated with soluble elastin peptides. After subtracting the blank value, the sample from the nonimmune column exhibited 4,112 cpm/500 ,l. 16 h and the sample from the immune column exhibited 4,125 cpm/500 Ml 16 h. The untreated platelet lysate sample exhibited 4,580 cpm/500 Ml -16 h. These results show that the IgG against neutrophil elastase did not remove the platelet elastolytic activity.
Affinity separation ofplatelet elastase-like activity using dog lung elastin. A 10-mg sample of 3H-dog lung elastin in 5 ml of 0.05 M Tris HCl-0. 14 M NaC1-0.2% Triton X-100 (pH 8.0) was mixed with 0.5 ml of the platelet lysate. The volume was brought to 15 ml with the same buffer. After stirring for 30 minutes at room temperature, the mixture was centrifuged to recover the elastin, which was then washed two times by suspension and centrifugation in the same buffer. The resulting washed elastin pellet was suspended in 15 ml of 1 M sodium acetate-0.01% Triton X-100 (pH 4.5) and stirred for 5 min at 5PC. The mixture was centrifuged at 2,000 g for 10 min at 50C, and the supernatant was recovered and concentrated to a volume of 0.5 ml using an Amicon UM05 membrane. This concentrated eluate from elastin was dialyzed in 0.05 M sodium acetate at pH 4.5 and used for determination of elastolytic activity.
When the elastin eluate was tested for rate of degradation of compound I and compound II, the ratio of activity for I vs. II was 6.19, a value close to that obtained by the same analysis of the platelet lysate (i.e., 5.47). Additionally, the elastin eluate activity was strongly inhibited by NaCI and was not affected by a1-antitrypsin.
Dependence ofplatelet elastase-like activity on pH. The elastin eluate was used to determine the pH profile of elastase-like activity using compound I as substrate (Fig. 6) . The pH optimum was between 8.5 and 9.0.
Determination ofthe apparent mass ratio ofthe platelet enzyme by high-pressure liquid chromatography. A sample of platelet lysate was dialyzed rapidly over a period of 2 h at 5PC in three changes of0.05 M sodium acetate (pH 4.5). The dialysate was centrifuged at 2,000 g for 10 min at 5PC to remove the platelet constituents which precipitated during dialysis. The resulting clear supernatant, 200 jAl, was applied to a protein column for high-pressure liquid chromatography and eluted at a flow rate of I ml/min (Fig. 7) . Fractions of 0.5 ml each were collected, and elastase-like activity was determined immediately, using an equal volume ofcompound I at twice the concentration usually employed in the fluorimetric assay. -75% of the activity applied to the column was recovered in the single activity peak obtained. The 250 Ad after dialysis in column buffer, was applied to both columns, and the activity for compound I was determined for the immune (A) and nonimmune (-) columns. R.I., relative intensity.
corresponds to an apparent mass ratio of 23,000 daltons. This value is close to that previously determined (26,000 daltons) for a platelet elastolytic enzyme (4).
Attempts to release elastase-like activity by platelet stimuli.
Preliminary studies were carried out to assess the possible release of elastase-like activity from platelets using low concentrations of effectors of the release reaction (37) . When thrombin (0.2 A/ ml), ADP (5 ,M), ADP in the presence of fibrinogen (0.25 mg/ ml), acid-soluble calf skin collagen (0. 19 mg/ml), and epinephrine (0.1 mM) were added to fresh washed platelets, little or no release of elastase-like or elastolytic activity could be detected. The platelets were, however, capable of undergoing normal aggregation (37) by these stimuli.
Discussion
Purified platelets were isolated essentially free of leukocytes. No neutrophils were observed when 10% (2.8 X 109 platelets) of those finally recovered from a unit of blood by the washing procedure were examined by differential cell counting. Lysis of 1 X 106 neutrophils results in release of at least I Mug of active elastase (38) . On the basis of the activity in the lysate for compound I, contamination of the washed platelets with 1.75 X I0' neutrophils/2.8 X 109 platelets would be required to give the observed activity. Based on the activity in the lysate for compound II, 5.4 X 105 neutrophils/2.8 X 109 platelets would be required to give the observed activity. Therefore, the observed activity for these substrates cannot be accounted for by neutrophil contamination. The failure of antibody specific for neutrophil elastase to adsorb the elastolytic activity from lysed platelets excludes the neutrophil as a source of elastase in platelets. Those studies (8, 9) that indicated the apparent absence of an elastase in platelets might be explained principally on the basis of low levels of observable activity using some substrates. As indicated by our data using SAPNA as substrate and by the data obtained with 3H-human lung elastin (Fig. 3) , the values were quite low and their validity had to be, in our experience, carefully evaluated. The availability of the fluorescence-labeled compounds I and II, as well as 3H-dog lung elastin, provided data more clearly interpretable, and provided the means ofbetter assessment of the effects of inhibitors.
Platelet lysate activity increased with time when tested with compounds I and II and SAPNA assays. Although our results do not further address this observation, the effect could be caused either by an associated inhibitor which dissociates or becomes inactive during the assay procedure or by the activation of a proenzyme (4) . Sodium chloride inhibits the platelet enzyme activity, whereas a1-antitrypsin has no effect. These agents have the opposite effect on neutrophil elastase. Inhibition of the platelet lysate elastase-like activity by DFP and PMSF, although partial in extent under the conditions utilized, indicates that the activity is due to a serine protease. The latter findings admit the possibility that more than one platelet elastase exists. Additionally, it is possible that a fraction of the observed activity for compound I could derive from an enzyme other than a serine protease type platelet elastase. The platelet enzyme ofthe present study therefore resembles those serine proteases which are poorly inhibited or not inhibited by a1-antitrypsin, such as clotting factor XII, plasma kallikrein, prekallikrein activator, and thrombin (39) .
The fact that the platelet lysate inhibits -5-10 times the quantity of neutrophil elastase as porcine trypsin or elastase (see Table II ) indicates that one or more inhibitors against neutrophil elastase other than a,-antitrypsin may exist in platelets. This observation further substantiates that the elastase-like and elastolytic activities in platelets are not due to neutrophil elastase.
Although the platelet lysate elastolytic activity is not inhibited by a1-antitrypsin, it is inhibited by a2-macroglobulin. Aig of the enzyme was present in 50 u1l of the lysate tested, and this concentration is equivalent to 0.175 ,ug of the enzyme/! X 109 platelets. These calculations lead to the conclusion that neutrophils contain much more elastase on a molar basis than do platelets. The platelets in a ml of blood, 0.26 X 109 platelets (33) , are thus estimated to contain 0.046 tig of elastase, whereas the neutrophils in I ml of blood contain -9 jig of elastase (38) . Determination of an apparent mass ratio of 23,000 daltons corresponding to the activity of the platelet enzyme proves that it is not bound to a2-macroglobulin in the lysate. The attempts made to effect release of the elastase-like and elastolytic activities from platelets using effectors at low concentrations (37) indicated that the enzyme could be located in the cytosol. Studies are currently being conducted to further investigate this possibility.
In conclusion, platelets contain an enzyme with elastolytic activity. The activity is not due to the presence of neutrophil elastase and it is not inhibited by a1-antitrypsin. Inhibition of the enzyme by a2-macroglobulin might have significance in situations such as adult respiratory distress syndrome, where influx of platelet and plasma components occur in the lung under degradative circumstances.
